COMPUGEN LTD

CGEN Nasdaq CIK: 0001119774

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Accelerated filer
State of Incorporation Israel
Business Address 26 HAROKMIM STREET, HOLON, L3, 5885849
Mailing Address 26 HAROKMIM STREET, HOLON, L3, 5885849
Phone 011-972-3-765-8585
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$35.34M
Net Income
$102.73M
Stockholders' Equity
$90.60M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 30, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC

Annual Reports

20-F March 2, 2026
  • Compugen's revenue significantly increased from $5 million to $15 million, driven by milestone payments and research funding from collaborations.
  • Lead drug candidate, COM701, continued to advance in multiple Phase 1/2 clinical trials, showing promising signs of activity in solid tumors.
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.